Skip Nav Destination
All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol: Presented in part at the 39th meeting of the American Society of Hematology, New Orleans, LA, December 1999.
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation
Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461): Presented in part at the 43rd annual meeting of the American Society of Hematology, Orlando, FL, December 10, 2001, and published in abstract form.59
Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome
Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000
Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma
Prognostic implications of declining plasma gelsolin levels after allogeneic stem cell transplantation
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm
Late complications following treatment for severe aplastic anemia (SAA) with high-dose cyclophosphamide (Cy): follow-up of a randomized trial
Issue Archive
December 15 2002
In this Issue
Table of Contents
INSIDE BLOOD
EDITORIALS
PLENARY PAPERS
ERRATA
PERSPECTIVE
REVIEW ARTICLES
CHEMOKINES
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol: Presented in part at the 39th meeting of the American Society of Hematology, New Orleans, LA, December 1999.
Clinical Trials & Observations
Martin S. Tallman,Janet W. Andersen,Charles A. Schiffer,Frederick R. Appelbaum,James H. Feusner,William G. Woods,Angela Ogden,Howard Weinstein,Lois Shepherd,Cheryl Willman,Clara D. Bloomfield,Jacob M. Rowe,Peter H. Wiernik
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation
Clinical Trials & Observations
Stephen P. Robinson,Anthony H. Goldstone,Stephen Mackinnon,Angelo Carella,Nigel Russell,Carmen Ruiz de Elvira,Goli Taghipour,Norbert Schmitz
Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care
Clinical Trials & Observations
Britt-Marie Svahn,Mats Remberger,Karl-Erik Myrbäck,Katarina Holmberg,Britta Eriksson,Patrik Hentschke,Johan Aschan,Lisbeth Barkholt,Olle Ringdén
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461): Presented in part at the 43rd annual meeting of the American Society of Hematology, Orlando, FL, December 10, 2001, and published in abstract form.59
Clinical Trials & Observations
John C. Byrd,Krzysztof Mrózek,Richard K. Dodge,Andrew J. Carroll,Colin G. Edwards,Diane C. Arthur,Mark J. Pettenati,Shivanand R. Patil,Kathleen W. Rao,Michael S. Watson,Prasad R. K. Koduru,Joseph O. Moore,Richard M. Stone,Robert J. Mayer,Eric J. Feldman,Frederick R. Davey,Charles A. Schiffer,Richard A. Larson,Clara D. Bloomfield
Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome
Clinical Trials & Observations
Paul G. Richardson,Carol Murakami,Zhezhen Jin,Diane Warren,Parisa Momtaz,Deborah Hoppensteadt,Anthony D. Elias,Joseph H. Antin,Robert Soiffer,Thomas Spitzer,David Avigan,Scott I. Bearman,Paul L. Martin,Joanne Kurtzberg,James Vredenburgh,Allen R. Chen,Sally Arai,Georgia Vogelsang,George B. McDonald,Eva C. Guinan
Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000
Clinical Trials & Observations
Reinhard A. Seger,Tayfun Gungor,Bernd H. Belohradsky,Stephane Blanche,Pierre Bordigoni,Paolo Di Bartolomeo,Terence Flood,Paul Landais,Susanna Müller,Hulya Ozsahin,Justen H. Passwell,Fulvio Porta,Shimon Slavin,Nico Wulffraat,Felix Zintl,Arnon Nagler,Andrew Cant,Alain Fischer
Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma
Clinical Trials & Observations
Apostolia M. Tsimberidou,Peter McLaughlin,Anas Younes,Maria A. Rodriguez,Fredrick B. Hagemeister,Andreas Sarris,Jorge Romaguera,Mark Hess,Terry L. Smith,Ying Yang,Ana Ayala,Alejandro Preti,Ming-Sheng Lee,Fernando Cabanillas
Prognostic implications of declining plasma gelsolin levels after allogeneic stem cell transplantation
Clinical Trials & Observations
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm
Clinical Trials & Observations
Stefan Fröhling,Richard F. Schlenk,Jochen Breitruck,Axel Benner,Sylvia Kreitmeier,Karen Tobis,Hartmut Döhner,Konstanze Döhner
GENE THERAPY
Third-generation, self-inactivating gp91phoxlentivector corrects the oxidase defect in NOD/SCID mouse–repopulating peripheral blood–mobilized CD34+ cells from patients with X-linked chronic granulomatous disease
Joachim Roesler,Sebastian Brenner,Anatoly A. Bukovsky,Narda Whiting-Theobald,Thomas Dull,Michael Kelly,Curt I. Civin,Harry L. Malech
Lentiviral gene transfer and ex vivo expansion of human primitive stem cells capable of primary, secondary, and tertiary multilineage repopulation in NOD/SCID mice
Wanda Piacibello,Stefania Bruno,Fiorella Sanavio,Sara Droetto,Monica Gunetti,Laurie Ailles,Francesca Santoni de Sio,Andrea Viale,Loretta Gammaitoni,Angelo Lombardo,Luigi Naldini,Massimo Aglietta
HEMATOPOIESIS
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
IMMUNOBIOLOGY
Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis
Frederique Ponchel,Ann W. Morgan,Sarah J. Bingham,Mark Quinn,Maya Buch,Robert J. Verburg,Judy Henwood,Susan H. Douglas,Aurelie Masurel,Philip Conaghan,Moji Gesinde,Julia Taylor,Alexander F. Markham,Paul Emery,Jacob M. van Laar,John D. Isaacs
NEOPLASIA
CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas
Frederic Tort,Silvia Hernàndez,Silvia Beà,Antonio Martı́nez,Manel Esteller,James G. Herman,Xavier Puig,Emma Camacho,Montse Sánchez,Iracema Nayach,Armando Lopez-Guillermo,Pedro L. Fernández,Dolors Colomer,Luis Hernàndez,Elias Campo
Human myeloma cells stimulate the receptor activator of nuclear factor-κB ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease
Nicola Giuliani,Simona Colla,Roberto Sala,Matteo Moroni,Mirca Lazzaretti,Silvia La Monica,Sabrina Bonomini,Magda Hojden,Gabriella Sammarelli,Sophie Barillè,Regis Bataille,Vittorio Rizzoli
RED CELLS
TRANSPLANTATION
BRIEF REPORTS
Late complications following treatment for severe aplastic anemia (SAA) with high-dose cyclophosphamide (Cy): follow-up of a randomized trial
Clinical Trials & Observations
Brief Report
CORRESPONDENCE
-
Cover Image
Cover Image
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals